Kyverna Therapeutics Inc (KYTX) PT Raised to $25 at Morgan Stanley
Tweet
Share
E-mailGet Alerts KYTX Hot Sheet
Price: $8.17 +1.11%
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst Michael Ulz raised the price target on Kyverna Therapeutics Inc (NASDAQ: KYTX) to $25.00 (from $20.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
- Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins
- Tata Motors Passenger Vehicles (TMPV:IN) PT Raised to INR375 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
